- Conditions
- Covid19
- Interventions
- KELEA Excellerated Water, Water Without an Elevated Level of KELEA
- Device
- Lead sponsor
- Institute of Progressive Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- South Pasadena, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 1,038
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stress
- Interventions
- Positive Affect Journaling
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Gambling, Pathological Gambling, Problem Gambling
- Interventions
- Personalized Feedback Intervention, Cognitive Behavioral Intervention
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 17 Years to 24 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Human Immunodeficiency Virus, Substance Related Disorder, Post Traumatic Stress Disorder
- Interventions
- Neutral Writing, Expressive Writing, Contingency Management
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
- Interventions
- Artesunate, Placebo
- Drug
- Lead sponsor
- Frantz Viral Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Alcohol; Use, Problem
- Interventions
- Experimental: Mobile Alcohol Expectancy Intervention
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Colorectal Cancer
- Interventions
- Epi proColon Test, Fecal Immunochemical Test (FIT)
- Device
- Lead sponsor
- Epigenomics, Inc
- Industry
- Eligibility
- 50 Years to 76 Years
- Enrollment
- 490 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Danville, Pennsylvania
- Conditions
- Schizophrenia
- Interventions
- RBP-7000, Placebo, Risperidone
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 32
- States / cities
- Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 25 more
- Conditions
- Healthy
- Interventions
- Contextualized Wish-Outcome-Obstacle-Plan (WOOP) intervention, Placebo
- Behavioral
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Pregnancy Related, Infant Development
- Interventions
- Mobile messaging
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 291 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hernia, Ventral, Pain Management
- Interventions
- Quadratus Lumborum (QL) Block, Placebo
- Procedure
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Atezolizumab Placebo, Paclitaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 8
- States / cities
- Stanford, California • Fort Myers, Florida • St. Petersburg, Florida + 5 more
- Conditions
- Aggressive, Defiant Disorder, Oppositional, Attention Deficit Hyperactivity Disorder
- Interventions
- Task-Based Grounding, Connected Care (Enhanced Treatment as usual)
- Behavioral
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 9 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Chronic Hepatitis B
- Interventions
- Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Schizophrenia
- Interventions
- AZD8529, Placebo to match AZD8529
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sepsis, Septic Shock, Sepsis, Severe, Volume Overload
- Interventions
- VExUS score
- Diagnostic Test
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
- Interventions
- Prevnar-13
- Biological
- Lead sponsor
- VA Eastern Colorado Health Care System
- Federal
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Lung Cancer (Diagnosis)
- Interventions
- Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Mild Cognitive Impairment (MCI), Amyloid Pathology
- Interventions
- Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation, Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation
- Device
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Any Solid Oral Medication
- Interventions
- Use of ReX to dispense and monitor solid oral medication therapy.
- Device
- Lead sponsor
- Dosentrx Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • Austin, Texas • Richmond, Virginia + 1 more
- Conditions
- Allergic Skin Reaction
- Interventions
- Hyaluronidase, Histamine, Saline
- Drug
- Lead sponsor
- Amphastar Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 253 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 5
- States / cities
- Eugene, Oregon • Lake Oswego, Oregon • Portland, Oregon + 2 more
- Conditions
- Cervical Myelopathy, Hip Fractures
- Interventions
- Cervical MRI, History & Physical Exam
- Diagnostic Test · Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Fishers, Indiana • Indianapolis, Indiana
- Conditions
- Hypersensitivity Pneumonitis
- Interventions
- Re-imagining Interventions for Support and Education in Hypersensitivity Pneumonitis (RISE-HP), Staying Well
- Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Interventions
- Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx)
- Drug · Diagnostic Test
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 40
- States / cities
- Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more